Patents
Sitemap › C07 - Organic chemistry › C07D - Heterocyclic compounds › C07D 401 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
Patents for C07D 401 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom (107,979)
10/2004
10/21/2004WO2004089930A1 4-fluoroquinolone derivatives and their use as kinase inhibitors
10/21/2004WO2004089922A2 Calcium channel inhibitors comprising benzhydril spaced from piperazine
10/21/2004WO2004089915A1 Piperazine derivative renin inhibitors
10/21/2004WO2004089914A1 Benzenesulphonamide derivatives as herbicides or desiccant/defoliant compounds
10/21/2004WO2004089912A1 Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds
10/21/2004WO2004089911A1 Pyrazole derivatives as gamma-secretase inhibitors useful in the treatment of alzheimer’s disease
10/21/2004WO2004089908A2 3-azabicyclo[3.2.1]octane derivatives
10/21/2004WO2004089903A1 Piperidine derivatives as renin inhibitors for the treatment of hypertension
10/21/2004WO2004089901A2 Phospholipase c inhibitors for use in treating inflammatory disorders
10/21/2004WO2004089892A2 Diarylmethyl and related compounds having beta2 andrenergic receptor agonist and muscarinic receptor antagonist activity
10/21/2004WO2004089890A2 Process and intermediates for preparing benzazepines
10/21/2004WO2004089882A2 Aromatic sulfonamides as peroxynitrite-rearrangement catalysts
10/21/2004WO2004089410A1 Preventive and/or remedy for neuropathic pain
10/21/2004WO2004089377A1 Calcium channel blockers comprising two benzhydril moieties
10/21/2004WO2004089373A1 4- (4-(heterocyclylalkoxy}phenyl)-1-(heterocyclyl-carbonyl)piperidine derivatives and related compounds as histamine h3 antagonists for the treatment of neurological diseases such as alzheimer’s
10/21/2004WO2004089370A1 4-phenyl-piperidine compounds and their use as modulators of opioid receptors
10/21/2004WO2004089367A1 Pharmaceutical use of substituted 1,2,4-triazoles
10/21/2004WO2004089362A1 2-cyanopyrroles and their analogues as ddp-iv inhibitors
10/21/2004WO2004089360A1 Polyamine compounds for treating chemokine receptor mediated diseases
10/21/2004WO2004089308A2 Di-aryl substituted pyrrole modulators of metabotropic glutamate receptor-5
10/21/2004WO2004089307A2 Acylated spiropiperidine derivatives as melanocortin-4 receptor agonists
10/21/2004WO2004089306A2 Di-aryl substituted triazole modulators of metabotropic glutamate receptor-5
10/21/2004WO2004089303A2 Di-aryl substituted pyrazole modulators of metabotropic glutamate receptor-5
10/21/2004WO2004089293A2 Hydroxamic acid compounds and methods of use thereof
10/21/2004WO2004089286A2 Novel compounds and compositions as protein kinase inhibitors
10/21/2004WO2004065380A8 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prpphylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
10/21/2004WO2004058144A3 Antibacterial agents
10/21/2004WO2004056786A3 Pyrimidine derivates for the treatment of abnormal cell growth
10/21/2004WO2004043369A3 Sulfonamides
10/21/2004WO2004009556A9 4-(substituted aryl)-5-hydroxyisoquinolinone derivative
10/21/2004WO2003097163A3 Using a selective inos inhibitor for the treatment of respiratory diseases and conditions
10/21/2004WO1995018619A9 Bicyclic fibrinogen antagonists
10/21/2004US20040210056 Water compatible sterically hindered alkoxyamines and hydroxy substituted alkoxyamines
10/21/2004US20040210054 Process for the preparation of diamine single-sided condensation products
10/21/2004US20040210052 Efficient synthesis of 5-heteroatom-containing-pyrazoles
10/21/2004US20040210051 Inhibitors of binding between vascular cell adhesion molecules and cells expressing vla-4 integrin; antiinflammatory agents
10/21/2004US20040209948 especially naphthalene sulfonamides, used for treating asthma
10/21/2004US20040209940 potent antibacterial activity against various bacteria including drug-resistant strains
10/21/2004US20040209939 Pyrrole derivatives
10/21/2004US20040209924 treatment of prostate or breast cancer
10/21/2004US20040209922 Pyridine matrix metalloproteinase inhibitors
10/21/2004US20040209921 CXCR4 chemokine receptor binding comounds
10/21/2004US20040209919 2-[(2-pyridyl)methylsulfinyl]benzimidazole derivative stabilized with an inorganic salt of magnesium, calcium, potassium, or sodium; gastric acid secretion inhibitors
10/21/2004US20040209918 Process for preparing benzimidazole-type compounds
10/21/2004US20040209915 substituted with an N- (p-hydroxy-alpha-hydroxybenzylaminoalkylpiperidinyloxy- (or -amino-)carbonylamino group; useful for identifying compounds having both beta 2 adrenergic receptor agonist and muscarinic receptor antagonist activity
10/21/2004US20040209914 Aromatic sulfone hydroxamic acids and their use as protease inhibitors
10/21/2004US20040209913 Bicyclic Heteroaromatic Alanines
10/21/2004US20040209912 Substituted isoquinoline derivatives and their use as anticonvulsants
10/21/2004US20040209905 Quinoline derivatives and quinazoline derivatives
10/21/2004US20040209904 Substituted quinazoline compounds useful as P38 kinase inhibitors
10/21/2004US20040209902 Aminoquinoline compounds
10/21/2004US20040209897 Mitogen activated protein kinase-activated protein kinase-2 inhibiting compounds
10/21/2004US20040209894 e.g., 1-(4-chloroanilino)-4-[2-(pyridin-3-yl)-ethyl]-isoquinoline and 5-[4-(tert-butyl)-anilino]-8-[(6-methoxy-pyridin-3-yl)-methyl]-[1,6]naphthyridine
10/21/2004US20040209893 treatment of a condition mediated by a tachykinin including substance P and other neurokinins by administering N-benzyl-2-phenylpiperazine-1-carboxamides, e.g., 2-(4-Fluoro-2-methyl-phenyl)-piperazine-1-carboxylic Acid (3,5-bistrifuoromethyl-benzyl)-methyl-amide Hydrochloride .
10/21/2004US20040209892 Heterocyclic compounds and methods of use
10/21/2004US20040209891 Treatment of type 2 diabetes with inhibitors of dipeptidyl peptidase IV
10/21/2004US20040209889 N-substituted nonaryl-heterocyclic nmda/nr2b antagonists
10/21/2004US20040209884 Fused azabicycic compounds that inhibit vanilloid receptor subtype 1(VR1) receptor
10/21/2004US20040209882 e.g., 2-{[4-(Cyclohexylmethyl-amino)-6-(3-fluoro-4-methoxy-phenylamino)-[1,35]triazin-2-ylamino]-methyl}-cyclopentanone; treating unwanted cellular proliferation, an inflammation mediated disease, or a hyperproliferative disease, or modulating a glycosidase enzyme
10/21/2004US20040209881 e.g., N-Cycloheptyl-N'(1-ethyl-pyrrolidin-2-ylmethyl)-6-(3-fluoro-4-methoxy-phenoxy)-[1,3,5]triazine-2,4-diamine; treating unwanted cellular proliferation, an inflammation mediated disease, or a hyperproliferative disease, or modulating a glycosidase enzyme
10/21/2004US20040209880 e.g., 6-(3-Chloro-4-methoxy-phenoxy)-N-cycloheptyl-N'-methyl-N'-(1-methyl-piperidin-4-yl)-[1,3 ,5]triazine-2,4-diamine; inhibit or block glycated protein produced induction of the signaling-associated inflammatory response in endothelial cells and inhibit smooth muscle proliferation.
10/21/2004US20040209879 Piperidinyl derivates as modulators of chemokine receptor activity
10/21/2004US20040209874 Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE)
10/21/2004US20040209872 Calcium channel blockers comprising two benzhydril moieties
10/21/2004US20040209868 Substituted indoles
10/21/2004US20040209865 use for reducing body weight and treating urinary incontinence; Melanin-concentrating hormone (MCH); 5-(4-chloro-phenyl)-2-[5-(2-pyrrolidin-1-yl-ethoxy)-pyridin-2-yl-ethynyl]-pyridine for example
10/21/2004US20040209863 5-chloro-N-(5-chloropyridin-2-yl)-2-[(4-{(Z)-(dimethylamino)[(methylsulfonyl)imino]methyl}benzoyl)amino]benzamide; treating thromboembolic disorders, optionally with other active agents
10/21/2004US20040209862 use treating Human Immunodeficiency Virus (HIV) , or genetically related retroviral, infection or a resulting acquired immunodeficiency syndrome (AIDS); 2-[4-(3,5-dichlorobenzyl)-3,5-diethyl-1H-pyrazol-1-yl]ethanol; reverse transcriptase inhibitors
10/21/2004US20040209860 compounds having a (biphenyl-2-yl)oxycarbonylamino- or (biphenyl-2-yl)aminocarbonylamino-substituted (2-7C)azacycloalkyl or (5-10C)azabicycloalkyl group; and a 2-(4-hydroxyphenyl)-2-hydroxyethylamino group; treating asthma or chronic obstructive pulmonary disease; providing bronchodilation
10/21/2004US20040209846 Heterocyclic analgesic compounds and methods of use thereof
10/21/2004CA2522214A1 4-phenyl-piperidine compounds and their use as modulators of opioid receptors
10/21/2004CA2522023A1 Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them
10/21/2004CA2521899A1 4- (4-(heterocyclylalkoxy}phenyl)-1-(heterocyclyl-carbonyl)piperidine derivatives and related compounds as histamine h3 antagonists for the treatment of neurological diseases suchas alzheimer's
10/21/2004CA2521875A1 Calcium channel blockers comprising two benzhydril moieties
10/21/2004CA2521653A1 Aromatic sulfonamides as peroxynitrite-rearrangement catalysts
10/21/2004CA2521433A1 Piperidine derivatives as renin
10/21/2004CA2521416A1 Polyamine compounds for treating chemokine receptor mediated diseases
10/21/2004CA2521400A1 Piperazine derivative renin inhibitors
10/21/2004CA2521399A1 Di-aryl substituted pyrrole modulators of metabotropic glutamate receptor-5
10/21/2004CA2521396A1 Di-aryl substituted triazole modulators of metabotropic glutamate receptor-5
10/21/2004CA2521348A1 Processes for the preparation of n-((((pyridinyloxy)-phenylamino) quinazolinyl)-allyl) acetamide derivatives and related compounds as well as intermediates of such processes and processes for the preparation of such intermediates
10/21/2004CA2521227A1 Substituted pyrazole compounds
10/21/2004CA2521201A1 Substituted pyrazoles for use in the prophylaxis or treatment of a disease which can be influenced by the binding of the substitued pyrazoles to 5ht receptors
10/21/2004CA2521184A1 Novel compounds and compositions as protein kinase inhibitors
10/21/2004CA2521000A1 Preventive and/or therapeutic agent for neuropathic pain
10/21/2004CA2520870A1 Di-aryl substituted pyrazole modulators of metabotropic glutamate receptor-5
10/21/2004CA2520611A1 Hydroxamic acid compounds and methods of use thereof
10/21/2004CA2520114A1 Acylated spiropiperidine derivatives as melanocortin-4 receptor agonists
10/21/2004CA2519882A1 Novel crystals of fluorobenzamide derivative
10/20/2004EP1468999A1 Substituted piperidine and piperazine derivatives as melanocortin-4 receptor modulators
10/20/2004EP1468996A1 Indole derivatives for the treatment of CNS disorders
10/20/2004EP1467989A1 Proline compounds as ns3-serine protease inhibitors for use in treatment of hepatitis c virus infection
10/20/2004EP1467988A1 Quinazoline(di)ones for invertebrate pest control
10/20/2004EP1467987A1 Preparation of lansoprazole and related compounds
10/20/2004EP1467986A1 Aza-cyclic compounds as modulators of acetylcholine receptors
10/20/2004EP1467985A1 Diamide invertebrate pest control agents
10/20/2004EP1467979A2 FUSED HETEROCYCLIC COMPOUNDS AND ANALOGS THEREOF: MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION
10/20/2004EP1467977A1 Novel antibacterial compounds:process for their preparation and pharmaceutical compositions containing them.
10/20/2004EP1467976A1 N-pyrazinyl-phenylsulphonamides and their use in the treatment of chemokine mediated diseases
10/20/2004EP1467975A1 Substituted alkyl uracils and the use thereof
1 ... 611 612 613 614 615 616 617 618 619 620 621 622 623 624 625 626 627 628 629 630 631 ... 1080